Can-Fite BioPharma (CANF) Stock Price, News & Analysis

Company Overview

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Key Stats

• Today's Range: $1.03 to $1.08
• 50-Day Range: $1.04 to $2.02
• 52-Week Range: $0.98 to $4.69
• Volume: 58,177 shs
• Average Volume: 238,806 shs
• Market Capitalization: $3.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

CANF Stock Analysis - Frequently Asked Questions

How have CANF shares performed this year?

Can-Fite BioPharma's stock was trading at $1.6250 at the beginning of the year. Since then, CANF stock has decreased by 35.4% and is now trading at $1.05.
View the best growth stocks for 2025 here.

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSE:CANF) announced its quarterly earnings results on Tuesday, November, 30th. The company reported ($1.90) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $1.00. The business had revenue of $0.25 million for the quarter.

When did Can-Fite BioPharma's stock split?

Can-Fite BioPharma's stock reverse split on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Can-Fite BioPharma's major shareholders?

Top institutional investors of Can-Fite BioPharma include Rhumbline Advisers (1.08%).

How do I buy shares of Can-Fite BioPharma?

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Can-Fite BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Meta Platforms (META), Broadcom (AVGO), Novo Nordisk A/S (NVO) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/30/2021
• Today: 5/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CANF
• CIK: 1536196
• Web: www.canfite.com
• Phone: 972-3-924-1114
• Fax: 972-3924-9378
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.00
• High Stock Price Target: $18.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +1,233.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.93
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $674,000.00
• Price / Sales: 5.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.76 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 3,540,000
• Free Float: N/A
• Market Cap: $3.72 million
• Optionable: Not Optionable
• Beta: 1.18